Stryker (SYK) Stock Forecast & Price Target

Stryker is supported by a diversified portfolio spanning orthopedics, MedSurg, and capital equipment, with leadership in operating room equipment and strong positions in hip and knee replacements, trauma, extremities, and orthopedic robotics, which helps balance cyclical pressure in any one end market. The company’s fundamentals also benefit from durable demand signals, including really strong capital demand, a strong backorder and order book, and trauma and extremities growing faster than market, while roughly one-fourth of revenue coming from outside the United States adds geographic diversification. Even with risks from U.S. utilization pressure, global competition, pricing sensitivity, and slower-than-expected orthopedic adoption, the long-term outlook remains constructive because Stryker can extend growth through ASC expansion, strategic M&A, and margin expansion initiatives that support profitability.

Stryker is facing a weaker fundamental setup because its 2026 organic growth estimate of 8% now trails the company’s own 8.3%-9.3% guidance, while EPS of $14.92 is slightly below the $14.95-$15.10 range, signaling that execution is no longer cleanly outpacing expectations. The bearish view is reinforced by multiple operating headwinds, including ongoing Peripheral Vascular supply issues that are now expected to push that franchise to about -5% year over year in 3Q and flat year over year in 4Q, softer gross margins, and the lingering impact of the cyberattack that makes 2H results more dependent on a recovery that may be harder to fully capture. In addition, slowing momentum in recent product cycles, slower-than-expected adoption in the ASC setting, and rising competition in orthopedic robotics all threaten to compress growth and reduce the case for multiple expansion, especially as roughly 25% of sales come from outside the U.S. and add another layer of exposure to uneven demand.